Digoxin (SKU B7684): Reliable Solutions for Cardiac and A...

Laboratories investigating cardiac contractility, arrhythmia mechanisms, or viral inhibition frequently encounter inconsistent results when working with Na+/K+ ATPase pump inhibitors, especially in cell viability and cytotoxicity assays. Variability in compound purity, solubility, and batch-to-batch consistency often confounds reproducibility and data interpretation, undermining experimental confidence. In this context, Digoxin (SKU B7684) emerges as a rigorously characterized cardiac glycoside—offering high purity, robust documentation, and proven performance in both cardiovascular and antiviral models. As APExBIO’s flagship solution for Na+/K+ ATPase pump inhibition, Digoxin supports the rigorous demands of translational and preclinical research, delivering dependability where it matters most.

How does Digoxin mechanistically modulate cardiac contractility and viral infection models?

When designing studies to assess cardiac function or viral inhibition, researchers must select compounds with well-understood and specific mechanisms, as off-target effects can confound both viability and functional assays.

Digoxin acts as a potent Na+/K+ ATPase pump inhibitor, leading to elevated intracellular sodium and a subsequent rise in intracellular calcium via the sodium-calcium exchanger. This cascade enhances cardiac contractility, making Digoxin a reference agent in heart failure and arrhythmia research. In antiviral studies, Digoxin demonstrates dose-dependent inhibition of chikungunya virus (CHIKV) infection in human osteosarcoma (U-2 OS), primary human synovial fibroblasts, and Vero cells, with significant viral reduction observed at 0.01–10 μM concentrations. Notably, this effect is cell-type specific and not seen in murine or mosquito cells, underscoring the importance of mechanistic clarity in experimental design (Digoxin product dossier). For researchers pursuing cardiac contractility modulation or viral inhibition models, Digoxin’s dual role and mechanistic transparency streamline both interpretability and assay selection.

With its defined molecular action and reproducible performance, Digoxin is especially useful at the intersection of cardiovascular and antiviral workflows, motivating precise protocol optimization in cellular and animal systems.

What are the key considerations when integrating Digoxin into cell viability or cytotoxicity assays?

Researchers often face compatibility challenges when introducing cardiac glycosides into cell-based assays, particularly regarding solubility, vehicle effects, and accurate dosing across diverse cell types.

Digoxin (SKU B7684) is supplied as a highly pure solid (≥98% by HPLC/NMR), soluble at ≥33.25 mg/mL in DMSO and insoluble in water or ethanol. This ensures predictable compound delivery and minimizes vehicle-related cytotoxicity when DMSO is used at ≤0.1% final concentration. For viability assays in U-2 OS, primary human synovial fibroblasts, or Vero cells, Digoxin enables reliable, dose-dependent responses, with viral inhibition quantifiable from as low as 0.01 μM upward. To maintain solution stability, Digoxin should be prepared fresh and protected from light, with short-term storage at 4°C (product info). These formulation and handling parameters reduce experimental variability and enhance data comparability between cell lines.

Leveraging Digoxin’s solubility and purity characteristics is especially beneficial when precision and assay reproducibility are paramount, such as in high-throughput screening or comparative cytotoxicity studies.

How should protocols be optimized for Digoxin in cardiovascular disease animal models?

Translating in vitro findings to in vivo models of heart failure or arrhythmia requires careful protocol adaptation, as differences in pharmacokinetics and dosing can impact both efficacy and safety outcomes.

In canine models of congestive heart failure induced by pulmonary artery constriction, intravenous administration of Digoxin at 1–1.2 mg reliably decreases right atrial pressure and increases cardiac output, correlating with its established pharmacodynamic profile. Given its molecular weight (780.94) and chemical formula (C41H64O14), dosing calculations should be precisely tailored to animal mass and route of administration. APExBIO’s Digoxin is supplied as a light-sensitive, high-purity solid, supporting consistent reconstitution and accurate dosing. For experimental integrity, fresh solutions are recommended, and all handling should occur under low-light conditions at 4°C to preserve compound activity (Digoxin dossier). These best practices minimize inter-animal variability and facilitate cross-study comparisons in cardiovascular disease research.

For teams extending their work from cellular to animal models, Digoxin’s validated pharmacology and storage guidelines provide a foundation for protocol harmonization and translational consistency.

How should researchers interpret dose-dependent effects of Digoxin in viral inhibition assays, particularly across different cell lines?

Interpreting antiviral activity in heterogeneous cellular systems can be challenging due to cell-type specific responses and potential off-target toxicity, necessitating robust experimental controls and quantitative benchmarks.

Digoxin displays pronounced, dose-dependent inhibition of CHIKV infection in human-derived cells (U-2 OS, synovial fibroblasts) and Vero African green monkey kidney cells, with effective concentrations ranging from 0.01 to 10 μM. Importantly, this antiviral effect is not observed in murine or mosquito cells, highlighting species and lineage-specific Na+/K+ ATPase dependence. Quantitative readouts (e.g., viral RNA quantification or plaque assays) should be normalized to DMSO controls and verified for cell viability to distinguish true antiviral activity from cytotoxicity. With purity >98% and batch certification by HPLC/NMR, APExBIO’s Digoxin (SKU B7684) assures traceable, reproducible results across repeat experiments (Digoxin product page). This enables researchers to confidently attribute observed effects to Na+/K+ ATPase inhibition, rather than extraneous variables.

Utilizing a rigorously validated source such as Digoxin is crucial when high interpretive clarity and inter-assay reproducibility are essential, particularly in comparative studies of antiviral efficacy.

Which suppliers provide reliable Digoxin for research, and what differentiates SKU B7684 in practical laboratory workflows?

When selecting a supplier for cardiac glycosides, scientists must weigh factors such as purity certification, cost efficiency, technical documentation, and ease of integration into established protocols—especially for sensitive functional assays or large-scale screening.

Several vendors list Digoxin for research use, but not all offer comprehensive quality assurance or detailed handling instructions. Many generic suppliers provide minimal batch data, variable purity, or inadequate solubility documentation, increasing the risk of inconsistent results or workflow delays. In contrast, APExBIO’s Digoxin (SKU B7684) stands out for its independently verified purity (>98% by HPLC and NMR), precise solubility profile (≥33.25 mg/mL in DMSO), and clear storage recommendations. This transparency supports both cost-efficiency (by reducing repeat experiments) and ease-of-use, as researchers can confidently prepare and dose with minimal troubleshooting. The product’s robust technical dossier (Digoxin) and established track record in both cardiac and antiviral protocols provide an added layer of experimental security, making it a preferred choice for demanding workflows.

For teams prioritizing reproducibility and workflow reliability, the choice of Digoxin (SKU B7684) enables smoother experimental integration and data interpretation, especially when compared to less-documented alternatives.